CLCF1 Exercise-induced Myokine Protocol for Investigating RANKL/OPG Bone Protection Mechanisms in Postmenopausal Osteoporosis

Postmenopausal osteoporosis (PMOP) represents a paradigmatic example of age-related musculoskeletal decline in which immune system dysregulation precipitates pathological bone loss^1,2,3. Although exercise is widely recognized as the most effective non-pharmacological intervention for preventing age-related bone deterioration, the precise molecular mechanisms underlying exercise-induced bone protection have remained elusive until recently⁴. The contemporary understanding of bone metabolism has evolved beyond traditional endocrinological frameworks to encompass complex osteoimmune interactions and exercise-induced myokines that govern skeletal homeostasis⁵.

The recent identification of cardiotrophin-like cytokine factor 1 (CLCF1) as an exercise-induced factor that combats age-related musculoskeletal decline represents a paradigm shift in understanding bone-muscle crosstalk⁶. This groundbreaking discovery explains the well-established bone-protective effects of exercise through a previously unknown molecular mechanism, positioning CLCF1 as the key mediator of exercise-induced osteoanabolism⁷. Transgenic mice overexpressing CLCF1 demonstrated enhanced bone formation, improved glucose tolerance, and superior physical performance compared to wild-type controls⁶, suggesting that CLCF1 supplementation could potentially mimic exercise benefits in sedentary or mobility-impaired populations.

Exercise-mimetic treatment is defined as pharmacological interventions that replicate exercise-induced CLCF1 kinetics, providing therapeutic benefits similar to physical activity through molecular pathways⁸. Cardiotrophin-like cytokine factor 1 (CLCF1), alternatively designated as neurotrophin-1 (NNT-1) or B-cell stimulatory factor-3 (BSF-3), belongs to the interleukin-6 (IL-6) cytokine superfamily and exhibits pleiotropic biological functions⁸. Originally characterized for its neurotrophic properties in spinal motor neuron survival and development, CLCF1's role as an exercise-induced myokine has emerged as a significant area of investigation. Recent clinical studies have validated CLCF1 as a biomarker for bone health status, demonstrating that CLCF1 protein levels in peripheral blood mononuclear cells are significantly decreased in postmenopausal women with osteoporosis compared with healthy controls⁹. These studies showed positive correlations between CLCF1 expression and bone mineral density at multiple skeletal sites, providing clinical validation that strengthens the translational potential of CLCF1-targeted therapeutic interventions.

The cytokines operate through heteromeric receptor complexes, including soluble ciliary neurotrophic factor receptors (sCNTFR) and cytokine receptor-like factor-1 (CRLF-1), to orchestrate diverse cellular responses^10,11. Recent mechanistic studies have elucidated the dual signaling paradigm whereby CLCF1 simultaneously inhibits bone resorption and promotes bone formation^2,6,7,9. This dual action occurs through differential signal transducer and activator of transcription (STAT) pathway activation: STAT1 phosphorylation mediates osteoclast suppression by interfering with receptor activator of the nuclear factor-κB ligand (RANKL)-induced nuclear factor-κB (NF-κB) signaling, whereas STAT3 activation in osteoblasts promotes the expression of bone formation markers, including alkaline phosphatase and osteocalcin.

Understanding how acute exercise responses translate to chronic bone adaptations remains critical for therapeutic development¹³. While acute CLCF1 elevation following single exercise bouts provides mechanistic insights, repeated acute responses over weeks to months may lead to sustained bone-protective effects through cumulative signaling and cellular adaptations¹⁴.

The rationale for investigating CLCF1 in osteoimmune pathophysiology stems from its established role in B-lymphocyte regulation and recognition that B cells constitute significant producers of both RANKL and osteoprotegerin (OPG)^12,13. The receptor activator of the nuclear factor-κB ligand (RANKL)/osteoprotegerin (OPG) axis serves as the central regulatory mechanism for osteoclast differentiation and bone resorption^14,15. Unlike other IL-6 family members that have demonstrated regulatory control over skeletal homeostasis through bone remodeling modulation, CLCF1's unique dual bone-protective mechanism offers superior therapeutic potential^16,17,18.

The advantages of this protocol over existing methodologies include its comprehensive approach to exercise osteoimmune investigation, incorporating both clinical correlation analysis and mechanistic cellular studies to provide translational insights into CLCF1-mediated bone metabolism regulation. The clinical relevance of this protocol is further enhanced by emerging evidence that CLCF1 levels can be modulated through lifestyle interventions, positioning it as an actionable therapeutic target for age-related bone disorders.

This protocol has been approved by the institutional research ethics committee (Protocol #2024-CHSD-0156) and adheres to the Declaration of Helsinki principles. All animal procedures complied with the institutional animal care and use committee guidelines (Protocol #2024-037). All the participants provided written informed consent.

1. Clinical sample collection and exercise intervention assessment

1. Participant recruitment and exercise history evaluation
   1. Recruit postmenopausal women aged 55-75 years with a minimum 1-year postmenopausal duration.
   2. Assess detailed exercise history, including frequency, intensity, type, and duration of physical activity over the past 6 months using standardized physical activity questionnaires.
   3. Categorize participants into sedentary (< 150 min/week), moderately active (150-300 min/week), and highly active (> 300 min/week) groups based on WHO exercise guidelines.
   4. Perform comprehensive medical history assessment and physical examination, including medication review and comorbidity screening.
   5. Obtain dual-energy X-ray absorptiometry (DXA) measurements using Hologic Discovery A densitometer with APEX software v4.5. Perform daily calibration with the spine phantom. Position the patient supine with legs elevated on a positioning block per International Society for Clinical Densitometry (ISCD) guidelines.
   6. Classify participants according to World Health Organization osteoporosis criteria (T-score ≤ -2.5 SD).
   7. Apply exclusion criteria: Prior anti-osteoporotic therapy within 12 months, immunosuppressive treatments, metabolic bone diseases, secondary osteoporosis, or contraindications to exercise testing.
2. Exercise-induced CLCF1 response assessment
   1. Collect baseline blood samples between 8:00-10:00 AM following 12 h overnight fasting in EDTA tubes.
   2. Implement standardized acute exercise protocol: 45 min moderate-intensity walking at 65-70 % maximum heart rate. Calculate maximum heart rate using the Karvonen formula (220 age)¹⁹. Perform exercise on a motorized treadmill with continuous heart rate monitoring via a chest strap monitor. Maintain walking speed at 3.5-4.5 km/h with grade adjustment to achieve the target heart rate.
   3. Collect post-exercise blood samples at 1 h, 4 h, and 24 h time points to assess CLCF1 kinetics, maintaining consistent collection conditions.
   4. Store serum aliquots at -80 °C for subsequent CLCF1 quantification. Use Human CLCF1 ELISA Kit with a detection range of 31.2-2000 pg/mL. Dilute samples 1:2 in assay diluent. Prepare a 7-point standard curve using 2-fold serial dilutions. Run samples in duplicate. Read plates at 450 nm with 540 nm wavelength correction. Accept coefficient of variation (CV) < 20 % between duplicates.
3. Longitudinal exercise intervention protocol
   1. Design a 12-week progressive exercise program with three sessions per week.
   2. Collect blood samples at baseline, 4, 8, and 12 weeks for CLCF1 trajectory analysis.
   3. Assess fitness improvements using VO2 max testing at baseline and endpoint.
   4. Correlate CLCF1 changes with BMD improvements measured by DXA at 12 weeks.
   5. Document training adaptations, including exercise tolerance and recovery patterns.

2. Enhanced peripheral blood mononuclear cell (PBMC) isolation and processing

1. Optimized PBMC isolation for CLCF1 analysis
   1. Collect 20 mL of venous blood samples in EDTA-containing tubes (5 mL EDTA per tube) under sterile conditions.
   2. Process samples within 2 h of collection for optimal cell viability and CLCF1 expression preservation.
      1. Dilute blood samples 1:1 with phosphate-buffered saline (PBS) at room temperature. Mix 20 mL of blood with 20 mL of PBS.
      2. Layer diluted blood over density gradient medium in 50 mL conical tubes. Use 15 mL density gradient medium per 20 mL diluted blood (1:1.33 ratio).
   3. Centrifuge at 400 × g for 30 min at room temperature without brake.
   4. Carefully aspirate the PBMC layer at the plasma-Ficoll interface using a sterile Pasteur pipette.
   5. Wash the cells twice with PBS containing 2% fetal bovine serum (FBS) by centrifugation at 300 × g for 10 min.
2. Cell viability assessment and CLCF1 baseline measurement
   1. Determine cell viability using the trypan blue exclusion method (target > 95% viability)²⁰.
   2. Assess baseline intracellular CLCF1 expression immediately after isolation.
   3. Adjust cell concentration to 1 × 10⁶ cells/mL in appropriate medium.
   4. Allocate cells for downstream applications or store in liquid nitrogen. Freeze PBMCs in freezing medium containing 90% FBS + 10% DMSO. Use a controlled-rate freezing container at -1 °C/min to -80 °C. Store 1 mL aliquots (5 × 10⁶ cells/vial) in cryovials.

3. Comprehensive quantitative gene expression analysis

1. RNA Extraction and purification with CLCF1-specific considerations
   1. Lyse 1 × 10⁶ PBMCs in 1 mL of RNA lysis reagent within 1 h of isolation.
   2. Add 200 µL of chloroform, vortex vigorously, and incubate for 3 min at room temperature.
   3. Centrifuge at 12,000 × g for 15 min at 4 °C to achieve phase separation.
   4. Transfer aqueous phase to a fresh tube, add an equal volume of isopropanol.
   5. Precipitate RNA by centrifugation at 12,000 × g for 10 min at 4 °C.
   6. Wash RNA pellet with 75% ethanol, air-dry, and dissolve in nuclease-free water.
   7. Assess RNA integrity using agarose gel electrophoresis or bioanalyzer (target RIN >7.0).
2. Reverse transcription and quantitative PCR with updated primer sets
   1. Quantify RNA concentration using spectrophotometric analysis (target A260/A280 ratio 1.8-2.2).
   2. Perform reverse transcription using 1 µg of total RNA with the reverse transcription reagent kit.
   3. Prepare qPCR reactions: Prepare 20 µL reactions containing 10 µL of Master Mix, 0.8 µL of each primer (10 µM stock, final 400 nM), 2 µL of cDNA template (50 ng), 6.4 µL of nuclease-free water. Run triplicates. Use a real-time PCR system.
   4. Use validated primer sequences:
      1. CLCF1 forward: 5'-CCTCCTGCTTCTTGCCTACC-3',
         reverse: 5'-TGCCACCATGTTTGTTTCCT-3'
      2. CRLF1 forward: 5'-TGAAGCTCATCCTGCAGTTC-3',
         reverse: 5'-CAGCATCTCCTCCTTGATGC-3'
      3. STAT1 forward: 5'-CAGCTTCAGCAGCTTGACTC-3',
         reverse: 5'-AAGGTCAGCGATGTCTTCAG-3'
      4. STAT3 forward: 5'-CAGCAGCTTGACACACGGTA-3',
         reverse: 5'-AAACACCAAAGTGGCATGTGA-3'
   5. Execute qPCR protocol: 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min.
   6. Analyze results using 2^(-ΔΔCt) method with β-actin normalization²¹.
3. Exercise-response gene panel analysis
   1. Include exercise-responsive genes: IL-6, TNF-α, IL-1β, BDNF, IGF-1, and myostatin.
   2. Use validated primer sequences:
      1. IL-6 forward: 5'-AGCCACTCACCTCTTCAGAAC-3',
         reverse: 5'-GCCTCTTTGCTGCTTTCACAC-3';
      2. TNF-α forward: 5'-CCCAGGGACCTCTCTCTAATC-3',
         reverse: 5'-ATGGGCTACAGGCTTGTCACT-3';
      3. IL-1β forward: 5'-ACAGATGAAGTGCTCCTTCCA-3',
         reverse: 5'-GTCGGAGATTCGTAGCTGGAT-3';
      4. BDNF forward: 5'-TAACATGGCTGCGCGTGTGT-3',
         reverse: 5'-CGAGTGGGTCACAGCGGCAG-3';
      5. IGF-1 forward: 5'-GCTCTTCAGTTCGTGTGTGGA-3',
         reverse: 5'-GCCTCCTTAGATCACAGCTCC-3';
      6. Myostatin forward: 5'-AGTGACGGGCTCTTTGGAAGA-3',
         reverse: 5'-GTTTCAGAGGCCGGTCAAGT-3'.
   3. Correlate exercise-induced changes in CLCF1 with other myokine expression patterns.
   4. Assess CLCF1/CRLF1 co-expression ratios as indicators of functional cytokine complex formation.

4. Enhanced protein expression analysis with STAT pathway focus

1. Protein extraction and quantification for STAT analysis
   1. Lyse PBMCs in lysis buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl pH 8.0) supplemented with protease and phosphatase inhibitor cocktails.
   2. Add some specific phosphatase inhibitors: sodium orthovanadate (1 mM) and sodium fluoride (50 mM) immediately before use.
   3. Incubate lysates on ice for 30 min with periodic vortexing at medium speed every 10 min.
   4. Centrifuge at 12,000 × g for 15 min at 4 °C to remove cellular debris.
   5. Quantify protein concentration using Bradford assay or BCA method²².
   6. Adjust protein concentrations to 2 µg/µL in a sample buffer and store at -80 °C until further analysis for western blotting applications.
2. Comprehensive western blot analysis with STAT signaling focus
   1. Prepare 10 mL of 10% SDS-PAGE gels using standard acrylamide/bisacrylamide solutions.
   2. Load 20 µg of protein per lane alongside pre-stained molecular weight markers and resolve at 120 V for 90 min.
   3. Transfer proteins to PVDF membranes at 100 V for 2 h at 4 °C using transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol).
   4. Block membranes with 50 mL of 5% non-fat dry milk in Tris-buffered saline with 0.1% Tween-20 (TBST).
   5. Incubate with primary antibodies overnight at 4 °C: Anti-CLCF1 (1:1,000); Anti-CRLF1 (1:1,000); Anti-OPG (1:1,000); Anti-RANKL (1:1,000); Anti-JAK2 (1:1,000); Anti-phospho-JAK2 (Tyr1007/1008, 1:1,000); Anti-STAT1 (1:1,000); Anti-phospho-STAT1 (Tyr701, 1:1,000); Anti-STAT3 (1:1,000); Anti-phospho-STAT3 (Tyr705, 1:1,000); Anti-β-actin (1:1,000)
   6. Wash membranes 3 times for 10 min each with 15 mL of TBST. Incubate with appropriate secondary antibodies for 1 h at room temperature.
   7. Detect protein bands using enhanced chemiluminescence substrate. Image using chemiluminescence imaging system with automatic exposure optimization. Quantify using densitometric analysis with ImageJ v1.53 gel analysis tool.
3. STAT1/STAT3 dual pathway analysis
   1. Calculate phospho-STAT1/total STAT1 and phospho-STAT3/total STAT3 ratios using ImageJ/Fiji software version 1.54f.
   2. Assess STAT1/STAT3 activation balance as indicator of CLCF1 functional activity.
   3. Correlate STAT activation patterns with RANKL/OPG expression ratios.
   4. Assess STAT1/STAT3 phosphorylation via Western blot at 0, 15, 30, 60, 120, and 240 min post-CLCF1 treatment. Normalize phospho-protein to total protein levels using densitometry.

5. Advanced CRISPR/Cas9-mediated gene knockout with validation

1. Enhanced lentiviral vector construction
   1. Design single-guide RNA (sgRNA) targeting CLCF1 gene sequence:
      TTGAAGTCTGGCTCGTTGAA-3'.
   2. Include additional sgRNA sequences for improved knockout efficiency:
      GCTTGAACGAGCCAGACTTC-3'.
   3. Clone sgRNAs into lentiviral vector using standard molecular cloning techniques.
   4. Verify construct integrity through DNA sequencing analysis.
   5. Assess sgRNA cutting efficiency using the T7 endonuclease I assay²³.
   6. Include pathway specificity validation using inhibitors: AG490 (JAK2, 50 µM), fludarabine (STAT1, 10 µM), and Stattic (STAT3, 5 µM).
   7. Perform rescue experiments using constitutively active STAT constructs to validate pathway necessity.
2. Optimized lentiviral transduction protocol
   1. Culture Raji cells in RPMI-1640 medium (500 mL) supplemented with 10% FBS. Maintain all cell cultures at 37 °C in a humidified incubator with 5% CO₂. Pre-equilibrate culture media for at least 30 min before use.
   2. Pre-treat cells with polybrene (8 µg/mL) to enhance transduction efficiency.
   3. Produce lentivirus using HEK293T cells with packaging and envelope plasmids via calcium phosphate transfection. Determine titer by p24 ELISA (> 10⁸ TU/mL required). Follow BSL-2 containment procedures²³.
   4. Transduce cells with lentivirus at a multiplicity of infection (MOI) of 100. Change media 24 h post-transduction. Select transduced cells using puromycin (4 µg/mL) for 7 days, then amplify a 500 bp region spanning the target site using the following PCR conditions: initial denaturation at 95 °C for 3 min, followed by 35 cycles of denaturation at 95 °C for 30 s, annealing at 60 °C for 30 s, and extension at 72 °C for 30 s, with a final extension at 72 °C for 5 min. For the T7 endonuclease assay, denature and reanneal the PCR products, digest with T7E1 endonuclease for 30 min at 37 °C, then analyze the products on a 2% agarose gel.
   5. Validate the gene knockout efficiency through western blotting and Sanger sequencing^24,25.
   6. Perform off-target analysis using GUIDE-seq or similar methodology²⁶.
      NOTE: Recent evidence demonstrates that CLCF1 secretion efficiency requires co-expression with CRLF1 chaperone protein. Consider dual knockout approaches for complete functional ablation²⁷.

6. Comprehensive co-culture system with exercise mimetics

NOTE: For translational validation, adapt to ovariectomized mouse models by administering rhCLCF1 at 10 µg/kg i.p. daily for 4 weeks, assessing BMD via micro-CT.

1. Advanced Raji-MG-63 co-culture setup
   1. Seed MG-63 osteoblast-like cells in 24-well plate lower chambers at a density of 2 × 10⁴ cells/well in a humidified incubator at 37 °C with 5% CO₂ and 95% humidity. Pre-equilibrate media in the incubator for 30 min before use. For enhanced translation, substitute with primary human osteoblasts (density 1 × 10⁴/well) from commercial sources.
   2. Place 0.4 µm pore size membrane inserts in wells containing MG-63 cells.
   3. Seed Raji cells (wild-type, CLCF1-knockout, or CLCF1-overexpressing) in upper chambers at density of 1 × 10⁵ cells/well.
   4. Maintain co-cultures in complete RPMI-1640 medium (2 mL in lower chamber, 1.5 mL in upper chamber) for specified experimental periods (7, 14, 21 days) at 37 °C with 5% CO₂.
   5. Include recombinant CLCF1 (5-10 ng/mL) treatment groups to assess dose-response relationships.
2. Exercise-mimetic CLCF1 treatment protocol
   1. Treat co-culture systems with physiological concentrations of recombinant CLCF1 (5-10 ng/mL) based on exercise-induced levels.
   2. Apply pulsatile CLCF1 treatment regimen: Apply CLCF1 for 2 h pulses at 0, 8, and 16 h on day 1, followed by continuous exposure for 24 h, then repeat cycle. Total treatment duration: 7 days with 9 total pulses.
   3. Assess time-dependent effects at 1 h, 4 h, 24 h, and 7 days post-treatment.
   4. Monitor STAT1/STAT3 phosphorylation kinetics in both cell populations via Western blot at 0, 15, 30, 60 min. Lyse cells in buffer (500 µL) with inhibitors, normalize to total STAT1/3 and β-actin.
3. Enhanced osteogenic differentiation assessment
   1. Induce osteogenic differentiation using standard osteogenic medium containing ascorbic acid (50 µg/mL), β-glycerophosphate (10 mM), and dexamethasone (10 nM). Change osteogenic medium every 3 days (2 mL lower chamber, 1.5 mL upper chamber). Prepare fresh ascorbic acid solution for each change; β-glycerophosphate and dexamethasone remain stable.
   2. Assess alkaline phosphatase (ALP) activity using colorimetric enzyme assay at days 7, 14, and 21²⁸. Use 500 µL of extraction volume. Read at 405 nm. Normalize to total protein content. Expected color range: light yellow (low) to dark yellow (high).
   3. Evaluate calcium deposition through Alizarin Red S staining and quantification at day 21. Extract with 500 µL of cetylpyridinium chloride, read at 540 nm, expected color range: light pink (low mineralization) to dark red (high mineralization).
   4. Quantify mineralization by measuring absorbance at 540 nm after cetylpyridinium chloride extraction.
   5. Analyze osteogenic gene expression: RUNX2, ALP, COL1A1, OCN, and OPGusing qPCR protocols described in step 3.2.
   6. Assess osteoclast-related markers: TRAP, cathepsin K, and RANKL in MG-63 cells.

7. Advanced statistical analysis and data interpretation

1. Comprehensive statistical methodology
   1. Perform normality testing using Shapiro-Wilk test for all continuous variables²⁹. Use non-parametric tests when normality assumptions are violated (p < 0.05).
   2. Apply Mann-Whitney U test for non-parametric comparisons between groups³⁰.
   3. Conduct Spearman correlation analysis for association studies between CLCF1 levels and clinical parameters³¹.
   4. Perform multiple regression analysis to assess independent predictors of BMD.
   5. Use repeated measures ANOVA for exercise intervention time-course analysis³².
   6. Apply Bonferroni correction for multiple comparisons³³.
   7. Set statistical significance threshold at p < 0.05 for all analyses.
2. Enhanced data presentation and analysis
   1. Present continuous data as mean ± standard deviation or median with interquartile range.
   2. Create correlation plots for CLCF1 expression versus BMD, lymphocyte counts, and exercise parameters using GraphPad Prism v9 for stats, ImageJ v1.53 for densitometry. No custom scripts are needed. Generate ROC via Prism's built-in tool; correlations via Spearman in Prism.
   3. Generate time-course plots for exercise-induced CLCF1 response kinetics.
   4. Develop receiver operating characteristic (ROC) curves for CLCF1 as an osteoporosis biomarker.
      NOTE: Representative western blot images were created using quantitative densitometric analysis.

Implementation of this protocol successfully demonstrates CLCF1's regulatory role in immune-mediated bone metabolism using multiple experimental approaches. The clinical validation studies show significant downregulation of CLCF1 expression in PMOP patients compared to healthy controls, as demonstrated in Figure 1A, quantitative PCR analysis of peripheral blood mononuclear cells demonstrated that relative CLCF1 mRNA levels were markedly reduced in the PMOP group (n = 109) compared to healthy postmenopausal controls (n = 94), with approximately 40% reduction in expression (p < 0.001). This finding was confirmed at the protein level, where western blot analysis revealed decreased CLCF1 protein (35 kDa) expression in PMOP patients, with densitometric quantification showing approximately 25% reduction compared to controls (p < 0.001; Figure 1B).

To establish the clinical relevance of reduced CLCF1 expression, we examined correlations between CLCF1 protein levels and various clinical parameters. Figure 2A demonstrates a significant positive correlation between relative CLCF1 protein levels in PBMCs and lumbar spine bone mineral density (r = 0.368, p < 0.001), while Figure 2B shows a similar correlation with femoral neck BMD (r = 0.382, p < 0.001), confirming the association across multiple skeletal sites. Analysis of immune parameters revealed that CLCF1 levels showed only weak correlation with total white blood cell counts (r = 0.162, p < 0.001; Figure 2C), but demonstrated a robust positive correlation with peripheral lymphocyte counts (r = 0.489, p < 0.001; Figure 2D), suggesting that CLCF1's relationship is primarily with the lymphocyte population, supporting its role in immune-bone crosstalk.

Mechanistic studies were conducted to elucidate the signaling pathways mediating CLCF1's bone-protective effects. Treatment with recombinant human CLCF1 (rhCLCF1) activated the JAK2/STAT3 pathway, as evidenced by increased phosphorylation of JAK2 and STAT3, which was completely abolished by the JAK2 inhibitor AG490 (Figure 3A). Validation using CLCF1-knockout cells demonstrated the consequences of CLCF1 deficiency on downstream signaling and bone metabolism markers. The knockout cells showed absent CLCF1 expression, reduced JAK2 and STAT3 phosphorylation, and decreased OPG expression, while RANKL levels remained unchanged (Figure 3B). Quantitative analysis revealed that CLCF1 knockout resulted in approximately 40% reduction in phospho-JAK2/JAK2 ratio and 50% reduction in phospho-STAT3/STAT3 ratio (both p < 0.01), along with significantly decreased OPG levels (p < 0.05) but maintained RANKL expression (Figure 3C). Consequently, the RANKL/OPG ratio was significantly elevated by approximately 2-fold in CLCF1-knockout cells (p < 0.001; Figure 3D), indicating a shift toward increased bone resorption potential.

The functional significance of CLCF1 in bone formation was validated using a co-culture system of B-lymphocytes and osteoblast-like cells. Figure 4A demonstrates that CLCF1 knockout in B cells led to reduced JAK2/STAT3 signaling and altered RANKL/OPG balance in the co-culture system. Functional assessment revealed that CLCF1 deficiency impaired osteoblast activity, with alkaline phosphatase activity reduced by approximately 20% in co-cultures containing CLCF1-knockout B cells (p < 0.01; Figure 4B). Furthermore, Alizarin Red S staining revealed visibly reduced calcium deposition in cultures with CLCF1-knockout cells compared to controls, with quantification of the extracted dye confirming approximately 25% reduction in mineralization (p < 0.01; Figure 4C).

Figure 5 provides a comprehensive workflow diagram illustrating the experimental design from the clinical sample collection through mechanistic validation, with clearly marked decision points and quality control checkpoints.

Successful protocol implementation should yield consistent results demonstrating CLCF1's regulatory role in immune-mediated bone metabolism. Suboptimal outcomes may result from inadequate sample preservation, insufficient cell viability during PBMC isolation, compromised antibody specificity for phosphoprotein detection, or variations in co-culture conditions that affect cell-cell interactions. The reproducibility of the findings across clinical correlation studies and mechanistic cell culture investigations validates the robustness of this methodological approach for investigating CLCF1-mediated osteoimmune interactions. See Table 1 for clinical characteristics of study participants.

Figure 1: Decreased CLCF1 expression in patients with postmenopausal osteoporosis. (A) Relative CLCF1 mRNA levels in peripheral blood mononuclear cells (PBMCs) from healthy controls (n = 94) and PMOP patients (n = 109). Expression was measured by quantitative RT-PCR and normalized to β-actin using the 2(-ΔΔCt) method. (B) Representative western blot and corresponding densitometric analysis of CLCF1 protein (35 kDa) in PBMCs from control and PMOP groups. β-actin (45 kDa) was used as a loading control. *Data are presented as mean ± SD. **P < 0.001 compared to the control group, Mann-Whitney U test. Please click here to view a larger version of this figure.

Figure 2: Correlation of CLCF1 protein levels with bone mineral density and lymphocyte counts. Scatter plots showing correlations between relative CLCF1 protein levels in PBMCs and clinical parameters in the study population (n = 203). (A) Correlation with lumbar spine bone mineral density (BMD) (r = 0.368, P < 0.001). (B) Correlation with femoral neck BMD (r = 0.382, P < 0.001). (C) Correlation with white blood cell (WBC) count (r = 0.162, P < 0.001). (D) Correlation with lymphocyte (LYMPH) count (r = 0.489, P < 0.001). Spearman correlation analysis. Please click here to view a larger version of this figure.

Figure 3: CLCF1 regulates the RANKL/OPG axis through JAK2/STAT3 signaling (A) Western blot analysis showing JAK2/STAT3 pathway activation by recombinant human CLCF1 (rhCLCF1, 10 ng/mL) and inhibition by AG490 (50 µM). (B) Comparison of protein expression between control (Ctrl) and CLCF1-knockout (CLCF1-KO) cells showing CLCF1 (35 kDa), JAK2 (125 kDa), phospho-JAK2 (125 kDa), STAT3 (125 kDa), phospho-STAT3 (86 kDa), OPG (48 kDa), RANKL (35 kDa), and β-actin (45 kDa). (C) Quantitative analysis of relative protein levels for phospho-JAK2/JAK2 ratio, phospho-STAT3/STAT3 ratio, OPG, and RANKL in control versus CLCF1-KO cells. (D) RANKL/OPG ratio demonstrating a significant increase in CLCF1-KO cells. *Data are presented as mean ± SD from three independent experiments. *P < 0.05, **P < 0.01, **P < 0.001, Student's t-test. Please click here to view a larger version of this figure.

Figure 4: CLCF1 deficiency impairs osteoblast differentiation and mineralization. (A) Quantitative analysis of relative protein levels for phospho-JAK2/JAK2, phospho-STAT3/STAT3, OPG, RANKL, and RANKL/OPG ratio in control versus CLCF1-knockout co-culture system. (B) Alkaline phosphatase (ALP) activity measurement in U/gprot showing reduced osteoblast differentiation. (C) Representative images of Alizarin Red S staining (upper panel) and quantification of mineralization by measuring absorbance at 540 nm after dye extraction (lower panel). *Data are presented as mean ± SD from three independent experiments. *P < 0.05, *P < 0.01, Student's t-test. Please click here to view a larger version of this figure.

Figure 5: Comprehensive experimental workflow. Schematic diagram illustrating the complete protocol workflow from participant recruitment through mechanistic validation. Key decision points and quality control checkpoints are indicated at each stage. The workflow integrates clinical assessment, molecular characterization, and functional validation to establish CLCF1's role in exercise-mediated bone protection. Please click here to view a larger version of this figure.

Table 1: Clinical characteristics of study participants. Demographic and clinical parameters of postmenopausal women enrolled in the study, comparing healthy controls (n = 94) and postmenopausal osteoporosis (PMOP) patients (n = 109). Data are presented as mean ± standard deviation (SD). Statistical comparisons between groups were performed using the Mann-Whitney U test for continuous variables. BMI, body mass index; WBC, white blood cell count; RBC, red blood cell count; HGB, hemoglobin; PLT, platelet count; BMD, bone mineral density. *P < 0.05 was considered statistically significant.

The protocol described herein provides a comprehensive methodological framework for investigating CLCF1's role as an exercise-induced mediator of bone protection through a systematic analysis of the RANKL/OPG axis. Recent breakthrough research has identified CLCF1 as an exercise-induced factor that combats age-related musculoskeletal decline, positioning it as a central mediator of exercise-induced bone protection^34,35,36. This enhanced protocol addresses a critical knowledge gap in osteoimmunology by providing a standardized methodology to investigate a newly identified exercise-mimetic factor with dual bone protective actions.

Critical steps identified through recent technical advances emphasize meticulous exercise intervention design to optimize CLCF1 response kinetics, careful preservation of STAT phosphorylation during sample processing, and standardized co-culture conditions for assessing bone-immune interactions. Evidence shows that CLCF1 secretion efficiency requires co-expression with CRLF1 chaperone protein, necessitating careful validation of knockout efficiency and consideration of dual-target approaches^7,9,34. The protocol incorporates recent discoveries showing that optimal CLCF1 concentrations for in vitro studies range from 5-10 ng/mL, reflecting exercise-induced physiological levels, while STAT1/STAT3 phosphorylation occurs within 1 h of CLCF1 treatment.

The clinical significance of this protocol is strengthened by recent validation studies demonstrating that CLCF1 alleviates bone loss in osteoporosis mouse models by suppressing osteoclast differentiation via activation of interferon signaling and repression of the NF-κB pathway⁹. Unlike traditional anti-resorptive therapies that primarily target osteoclasts, CLCF1-based interventions may offer the potential to simultaneously promote bone formation while inhibiting resorption through dual STAT signaling pathways^37,38. Mechanistic studies have revealed that CLCF1 exerts anti-osteoclastogenic functions via STAT1 phosphorylation, while promoting osteoblast differentiation through STAT3 activation, providing a sophisticated regulatory mechanism for bone protection.

The JAK2/STAT3 pathway plays a crucial role in bone metabolism, with STAT3 mediating the anabolic signals in osteoblasts and regulating bone formation. Clinical evidence from our protocol aligns with recent findings that JAK2/STAT3 pathway activation promotes osteoblast differentiation and bone formation³⁹. The protocol's validation of this dual mechanism through multiple experimental approaches provides robust evidence for CLCF1's unique position in the cytokine hierarchy regulating skeletal homeostasis.

For weak phospho-STAT signals, add fresh phosphatase inhibitors and process samples on ice immediately. For low knockout efficiency, optimize MOI to 150 and extend puromycin selection. For variable co-culture, ensure consistent seeding densities and media pH (7.2-7.4)¹⁹.

Compared with in vivo ovariectomized models, this protocol offers cost-effective, ethical in vitro alternatives with precise control over variables⁴⁰. Unlike single-cell assays, our co-culture mimics osteo-immune crosstalk better, enabling real-time signaling studies^10,41.

The limitations of this methodological approach include reliance on cell line models that may not fully recapitulate primary cell behavior and the complex exercise-induced tissue microenvironment. While MG-63 and Raji lines provide reproducible models, they may overexpress certain pathways compared to primary cells, potentially exaggerating CLCF1 effects. To mitigate this, future studies should validate primary human osteoblasts/B cells (e.g., from PMOP donors), which could show subtle responses but better clinical relevance¹⁰. Future applications should incorporate three-dimensional culture systems and direct assessment of exercise-conditioned media to better model physiological conditions. Additionally, the protocol focuses primarily on acute exercise responses; however, longitudinal training studies are needed to assess chronic adaptations in CLCF1-mediated bone protection (acute responses may not capture chronic adaptations; longitudinal data could reveal sustained CLCF1 upregulation, as in Ref²¹).

The therapeutic applications and broader significance of this protocol extend beyond immediate bone health considerations, offering insights into myokine-mediated tissue crosstalk and potential avenues for developing exercise mimetic therapies. Recent studies have highlighted the role of other IL-6 family cytokines, such as IL-11, in bone metabolism, positioning CLCF1 within the broader framework of cytokine-mediated bone regulation⁴². The standardized methodology facilitates translational research efforts aimed at developing targeted interventions for osteoporosis, whereas the protocol's applicability to broader exercise physiology research provides a foundation for investigating exercise-induced protective factors in aging populations. Before clinical translation, preclinical in vivo validation is essential for efficacy and translation⁹.